Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.40 +0.4%	$2.29	$0.40 ▼ $3.10	$192.68M	2.05	2.20 million shs	643,333 shs
IMNM Immunome	$8.40 -1.3%	$8.67	$5.15 ▼ $16.81	$740.47M	1.92	902,919 shs	984,556 shs
KALV KalVista Pharmaceuticals	$15.17 -0.3%	$12.67	$7.30 ▼ $16.32	$760.30M	-0.04	574,849 shs	1.42 million shs
SNDX Syndax Pharmaceuticals	$9.21 -6.5%	$9.95	$8.58 ▼ $25.07	$847.57M	0.7	1.86 million shs	1.71 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+0.42%	0.00%	-12.73%	+281.13%	+70.21%
IMNM Immunome	-1.29%	-1.75%	-8.70%	+17.15%	-40.68%
KALV KalVista Pharmaceuticals	-0.33%	+1.47%	+17.05%	+29.22%	+1.40%
SNDX Syndax Pharmaceuticals	-6.50%	+5.26%	-10.15%	-16.65%	-62.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.1523 of 5 stars	3.5	1.0	4.7	2.4	1.7	1.3
IMNM Immunome	2.0071 of 5 stars	3.5	0.0	0.0	3.6	2.5	0.0
KALV KalVista Pharmaceuticals	4.036 of 5 stars	3.6	1.0	4.4	3.1	1.7	0.6
SNDX Syndax Pharmaceuticals	3.0706 of 5 stars	3.5	0.0	4.4	2.5	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	122.22% Upside
IMNM Immunome	3.00	Buy	$23.33	177.78% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	73.27% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$34.10	270.25% Upside

Current Analyst Ratings Breakdown

Latest CTMX, IMNM, SNDX, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$37.00 ➝ $35.00
7/10/2025	SNDX Syndax Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$147.56M	1.31	$0.36 per share	6.60	($0.01) per share	-240.00
IMNM Immunome	$9.04M	80.85	N/A	N/A	$2.27 per share	3.70
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	33.47	N/A	N/A	$3.38 per share	2.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	5.00	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest CTMX, IMNM, SNDX, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IMNM Immunome	-$0.52	N/A	N/A	N/A	$1.03 million	N/A
8/7/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$0.99	N/A	N/A	N/A	N/A	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
IMNM Immunome	N/A	10.49	10.49
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
IMNM Immunome	44.58%
KALV KalVista Pharmaceuticals	N/A
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
IMNM Immunome	8.60%
KALV KalVista Pharmaceuticals	10.50%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
IMNM Immunome	40	87.01 million	79.53 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

CTMX, IMNM, SNDX, and KALV Headlines

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts

3 hours ago | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade

July 15 at 2:45 PM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group

July 15 at 11:19 AM | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at The Goldman Sachs Group

July 13 at 2:27 AM | americanbankingnews.com

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

July 12, 2025 | msn.com

The Goldman Sachs Group Initiates Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)

July 10, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 6.7% - Time to Buy?

July 9, 2025 | marketbeat.com

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML

July 9, 2025 | msn.com $https://www.msn.com/en-us/money/general/syndax-s-revuforj-granted-fda-priority-review-for-relapsed-refractory-mutant-npm1-aml/ar-AA1IeAsC$

Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals

July 8, 2025 | seekingalpha.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26, 2025 | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25, 2025 | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 24, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/24/3104643/0/en/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

Syndax reports publication of revumenib data from BEAT AML trial

June 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, IMNM, SNDX, and KALV Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.40 +0.01 (+0.42%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.42 +0.02 (+1.00%)

As of 07/15/2025 07:50 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Immunome NASDAQ:IMNM

$8.40 -0.11 (-1.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$8.40 +0.00 (+0.06%)

As of 07/15/2025 07:45 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

KalVista Pharmaceuticals NASDAQ:KALV

$15.17 -0.05 (-0.33%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$14.69 -0.48 (-3.16%)

As of 04:01 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.21 -0.64 (-6.50%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$9.38 +0.17 (+1.90%)

As of 07/15/2025 07:40 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time